Does biosimilar competition impact the reimbursement policy of the originator reference products? Given the excessive costs associated with biological and biosimilar drugs, the price behavior of this class of medicines is particularly important from industry and societal perspective. It is known that the availability of biosimilars can lead to rapid price reductions, particularly in markets… Czytaj dalej Does biosimilar competition impact the reimbursement policy of the originator reference products?
Miesiąc: grudzień 2021
TOP10 reimbursement value in Poland – September 2021
In September, there were significant changes in the TOP10 reibursement value for brands. For the whole market, #Keytrude moved to the 1st place from 4th in the ranking, while #Spinraza fell to 4th place. #Opdivo and #Neoparin swapped places – Opdivo moved to 2nd place from 3rd.The total reimbursement value for the current year is… Czytaj dalej TOP10 reimbursement value in Poland – September 2021